

IN THE CLAIMS

Please cancel claims 8, 13-17, 20-32 and 37-38 without prejudice, and amend claims 9, 10, 18 and 36, as follows:

- 1.-6. (Canceled)
7. (Previously Presented) A pharmaceutical composition comprising a herpes simplex virus (HSV) polypeptide, wherein the HSV polypeptide is up to 15 amino acids in length and comprises amino acids 475-483 of UL26 (SEQ ID NO: 9), and a pharmaceutically acceptable carrier.
8. (Canceled)
9. (Currently Amended) The pharmaceutical composition of claim 7, wherein the polypeptide consists essentially of amino acids 475-483 of UL26 (SEQ ID NO: 9).
10. (Currently Amended) The pharmaceutical composition of claim 7, wherein the polypeptide is a fusion protein, wherein the HSV polypeptide is fused to an unrelated immunogenic protein.
11. (Original) The pharmaceutical composition of claim 10, wherein the fusion protein is soluble.
12. (Original) The pharmaceutical composition of claim 7, further comprising an adjuvant.
- 13.-17. (Canceled)
18. (Withdrawn) A pharmaceutical composition comprising ~~the~~ a polynucleotide of claim 13 that encodes a polypeptide consisting of up to 15 amino acids and comprising amino acids 475-483 of UL26 (SEQ ID NO: 9); and a pharmaceutically acceptable carrier.
19. (Withdrawn) The pharmaceutical composition of claim 18, further comprising an adjuvant.
- 20.-32. (Canceled)

33. (Original) A method of inducing an immune response to an HSV infection in a subject comprising administering the composition of claim 7 to the subject.
34. (Withdrawn) A method of inducing an immune response to an HSV infection in a subject comprising administering the composition of claim 18 to the subject.
35. (Previously Presented) A method of treating an HSV infection in a subject comprising administering the composition of claim 7 to the subject.
36. (Withdrawn) A method of treating ~~or preventing~~ an HSV infection in a subject comprising administering the composition of claim 18 to the subject.
- 37.-38. (Canceled)